History

    • Dirk Dembski new CEO
    • Dr. Alexander Baratta replaces Dr. Detlef Wilke in the Supervisory Board
  • Spinevisc

    • Listing of curasan shares at stock exchange terminated
    • curasan sustainably capitalized by DONAU INVEST Beteiligungs-Ges.m.b.H., Vienna /Austria
    • Dr. Alexander Baratta new CEO
  • Spinevisc

    • Product launch Spinevisc©
    • Torben Sorensen new CEO
    • Dr. Kurt Berger replaces Dr. Tomas Kahn in the supervisory board
    • Capital increase by um 2.9 million Euro
    • Issuance of convertible bond 2019/2024
    • Isabella de Krassny replaces Prof. Dr. Honold in the supervisory board
  • 1988

    Curasan_historie_0016_260315-4873

    • Austrian investor takes a share of about 1.7 m Euros
    • Markus Lederer new Commercial Director
    • New European investor takes a share of about 1.2 m Euros
    • 30th Company Anniversary
  • 1988


    Dr. Tomas Kahn, CEO Michael Schlenk, Dr. Detlef Wilke, Prof. Dr. Dirk Honold

    • Investment of 2.25 Mio Euros by strategic Investor (Chindex, Fosun-group, China)
    • New Supervisory Board elected by Annual General Meeting
    • Distribution Agreement with Foshion Medical for dental products in China
    • Management change: Christine Uekert new CFO
  • 1988

    • Capital increase by 1.0 million Euros
    • FDA-approval for CERASORB® Ortho FOAM in the US
    • „Meet the Experts“ – Support of symposium for bone regeneration in orthopaedics, trauma and spine
    • Management change at curasan Inc., USA (Shane Ray, see pic)
    • Strategic Investor takes a share of 1 million Euros
  • 2015

    Curasan_historie_0009_260315-4927

    • 1.5 million units CERASORB® sold
    • Relaunch of synthetic hydroxyapatite Osbone® in the dental segment
    • Capital increase by 1.0 million Euros
    • Successful settlement of legal dispute with Stryker S.A.
  • 2014

    • Change in Management Board: Michael Schlenk new CEO
    • Initiation of the company restructuring
    • Capital increase by 1.4 million Euros
    • Product launch of Ceracell Foam® in the dental segment
  • 2013

    Curasan_historie_0010_260315-4774

    • FDA-approval for Osseolive® Dental
    • CE-certification for Ceracell Foam®
    • Acquisition of oral regeneration business from Riemser Pharma GmbH
  • 2012

    Produktgalerie_CERASORB-Paste_12

    • CE-certification for pasty bone regeneration material out of a syringe
  • 2011

    Produktgalerie_1290x690_osbone_04

    • FDA-approval for Osbone® Dental in the US
    • CE-certification for Osseolive®
  • 2009

    Curasan_historie_Cerasorb_Mio

    Curasan_historie_0004_260315-5135

    • 1 million units of CERASORB® sold
    • Inauguration of the new R & D and manufacturing site in Frankfurt
  • Produktgalerie_1290x690_osbone_03

    • CE-certification of Osbone®
    • Founding of new curasan Inc, the US subsidiary to focus on the orthopaedic, spine, and trauma market
  • 2008

    Curasan_historie_dental

    • Sale of the then existing dental division to RIEMSER ARZNEITMITTEL AG
  • 2005

    Produktgalerie_Curavisc_02

    • Product launch Curavisc®
  • 2004

    Cerasorb_M_Granulat_06

    • product launch of CERASORB® M
  • 2003

    Curasan_historie_0008_260315-5056

    • Product launch of CERASORB® Ortho in the USA
    • FDA-certification of CERASORB® production site
    • Sale of pharmaceuticals business
  • 2002

    • FDA-approval for CERASORB® Ortho for use in orthopaedics and traumatology
  • 2001

    curasan_stypro_02

    • Acquisition of Pro-tec Medizinische Produkte GmbH
    • launch of stypro®
  • 2000

    Pressemitteilungen_008

    • transformation into a public company (curasan AG) and Initial Public Offering (IPO)
  • 1999

    Curasan_historie_0012_260315-4827

    • First clinical results on CERASORB®
  • 1998

    Curasan_historie_0017_shutterstock_132405758

    • Start of clinical studies with CERASORB®
  • 1997

    Curasan_historie_dental2

    • European certification of CERASORB® for dentistry and maxillofacial surgery
  • 1988

    Curasan_historie_0016_260315-4873

    • Founding of curasan Pharma GmbH
      by Hans-Dieter Rössler
    • launch of local anaesthetics and antibiotics